How Much Weight Have People Lost on Ozempic? An In-Depth Analysis

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has become one of the most studied medications for chronic weight management, with clinical evidence demonstrating sustained weight loss in the majority of users. A landmark 2021 trial published in the New England Journal of Medicine found that participants lost an average of 15.3 kg (34 pounds) over 68 weeks compared to just 2.6 kg in the placebo group. Understanding real-world weight loss outcomes can help you set realistic expectations and make informed decisions about your health journey.

Clinical Trial Data: Average Weight Loss on Semaglutide

The STEP trials—a series of four randomized controlled studies—measured semaglutide's effectiveness across different populations. Participants receiving the highest dose (2.4 mg weekly) experienced weight reductions ranging from 15% to 22% of their starting body weight. For example, a person weighing 250 pounds might lose 37 to 55 pounds over the course of treatment. These results represent some of the most substantial weight loss outcomes achieved with any injectable medication in modern medicine.

Not every participant achieved the same results. In the STEP 1 trial, approximately 86% of semaglutide users lost at least 5% of their body weight, while 69% lost at least 15%. This variation underscores an important principle: semaglutide works as a metabolic tool that enhances your body's natural hunger and satiety signals, but your individual response depends on multiple biological and behavioral factors. Starting with consistent dosing and lifestyle changes maximizes your likelihood of reaching meaningful weight loss milestones.

Real-world data from clinical practices show similar patterns. Patients typically experience noticeable appetite reduction within the first two weeks and gradual weight loss acceleration over the first three months. By month six, most users report stable weight loss momentum that continues through month twelve, though the rate of loss may slow as your body adjusts. This timeline helps explain why commitment to the medication for at least three to six months is critical for evaluating whether it works for you.

How Genetics Influence Your Personal Weight Loss Outcome

Your genetic makeup plays a significant role in how your body responds to semaglutide. Specific variants in genes like GLP1R, GIPR, FTO, and MC4R influence how effectively the medication activates your satiety pathways and regulates appetite hormones. Someone with a genetic predisposition toward higher insulin sensitivity might experience faster initial weight loss, while others may respond more gradually but achieve equally impressive long-term results. PlexusDx's Precision Peptide Genetic Test examines 14 metabolic pathways and 150+ genetic insights to identify which peptide-based therapies align best with your biology.

The FTO rs9939609 variant, for instance, is associated with increased appetite drive and metabolic efficiency variations. Individuals carrying certain FTO variants often benefit from earlier semaglutide dose escalation or combination therapy approaches. Understanding your genetic profile removes guesswork from treatment selection and dosing strategy, allowing PlexusDx to customize your therapy for faster, more predictable results. This precision approach transforms weight loss from a trial-and-error process into a science-backed pathway matched to your unique peptide responsiveness.

Factors That Affect Individual Weight Loss Variability

Beyond genetics, several modifiable factors shape your weight loss trajectory on semaglutide. Dietary consistency plays a central role—the medication suppresses appetite, but choosing whole foods and adequate protein still matters for preserving muscle mass and sustaining energy. Physical activity, sleep quality, stress management, and baseline metabolic health all influence how quickly pounds drop and how long results last. Someone with well-controlled blood sugar and regular exercise typically sees faster results than a sedentary person with insulin resistance, even on identical medication doses.

Age and starting weight also affect velocity. Younger individuals often experience faster initial weight loss due to higher metabolic flexibility, while older adults may lose weight more steadily but sustainably. People starting at higher body weights frequently lose more total pounds but similar percentages compared to those starting closer to goal weight. Your baseline activity level matters too—someone transitioning from a sedentary lifestyle often experiences compounded benefits from both the medication and newly adopted movement habits.

Medication adherence and dosing consistency determine whether results plateau or continue advancing. Missing doses or delaying dose increases slows momentum. Conversely, individuals who follow their prescribed schedule and gradually increase to their target dose as directed typically achieve the full weight loss potential shown in clinical trials. PlexusDx's model ensures you remain on a consistent pricing plan—your dose may go up, but your cost stays the same—removing financial barriers to optimal dosing.

Comparing Semaglutide to Other GLP-1 Treatment Options

Semaglutide is one of several GLP-1 medications available, each with slightly different pharmacology and weight loss profiles. Tirzepatide, a dual GLP-1/GIP receptor agonist, produces average weight loss of 20-22% in clinical trials—roughly 4-7 percentage points higher than semaglutide alone. This difference reflects tirzepatide's dual mechanism, activating both the GLP-1 receptor and the gastric inhibitory peptide (GIP) pathway. However, semaglutide remains highly effective, costs less to start ($149/month vs. $249/month for compounded tirzepatide), and has longer safety data in real-world use.

PlexusDx offers both semaglutide and tirzepatide formulations as standalone treatments, plus GLP-Squared—a dual-compound combination that layers both mechanisms in a single injection. For patients whose genetic testing reveals strong GLP-1 pathway responsiveness, semaglutide injection starting at $149/month delivers excellent results at the lowest entry price. For those with genetic profiles suggesting superior dual-pathway activation, tirzepatide or GLP-Squared may optimize outcomes. Your Precision Peptide Genetic Test results guide this decision, ensuring you choose the medication most aligned with your biology.

Oral formulations (semaglutide at $249/month or tirzepatide at $279/month) offer convenience for injection-averse patients, though absorption is lower and weight loss typically trails injectable versions by 3-5 percentage points. PlexusDx microdose GLP-1 protocol at $129/month provides a lower-cost entry point for dose-sensitive individuals. All options are covered through HSA/FSA accounts and available in all 50 states without insurance requirements, making personalized GLP-1 therapy accessible regardless of your insurance status.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight should I expect to lose in my first month on semaglutide?

Most people lose 2-5 pounds in the first month as appetite suppression takes hold and water weight decreases. Significant fat loss typically accelerates in months two through four. PlexusDx's consistent $149/month pricing for semaglutide injection removes the pressure to see dramatic results immediately, allowing your body to adapt safely while building sustainable habits.

Will my weight loss plateau after a certain point?

Weight loss plateaus are common around months 4-6 as your body adapts to the medication. Plateaus typically last 2-4 weeks before resuming. Continuing consistent dosing, gradually increasing to your target dose, adding or adjusting exercise, and maintaining dietary improvements help overcome plateaus. Some patients benefit from dose optimization or switching to a dual-pathway compound like GLP-Squared.

How does compounded semaglutide from PlexusDx compare to brand-name Ozempic?

PlexusDx semaglutide is manufactured by licensed 503A compounding pharmacies using the same active ingredient as Ozempic, meeting strict USP standards for purity and potency. Compounded semaglutide costs $149/month versus $900-1,200 for brand Ozempic, making it accessible without insurance. PlexusDx serves all 50 states with no membership fees and HSA/FSA eligibility.

What happens to weight loss if I stop taking semaglutide?

Most people gradually regain weight within 6-12 months of discontinuing semaglutide, though the regain is usually slower than the original weight gain. This is why semaglutide is considered a long-term maintenance therapy rather than a temporary fix. Some people remain on treatment indefinitely; others cycle off once they've achieved goals and established new eating patterns. Discuss long-term strategy with your PlexusDx provider.

Can the Precision Peptide Genetic Test predict exactly how much weight I'll lose?

The Precision Peptide Genetic Test ($99 after your first month) maps your 14 metabolic pathways and 150+ genetic insights to reveal your responsiveness to GLP-1, GIP, and melanocortin pathways. While it cannot predict exact pounds lost, it identifies your genetic predisposition to respond robustly or moderately to semaglutide versus tirzepatide, allowing PlexusDx to recommend the medication and dosing strategy most likely to maximize your individual results.

Related Reading

• Ozempic For Losing Weight
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.